

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approvals for drug production and registration for Sodium Lactate Ringer's Irrigation Solution (3000ml) and Bumetanide Injection (2ml:1mg) from National Medical Products Administration of China, both being under type 3 chemical drug and regarded as passing the consistency evaluation.

The Group’s Sodium Lactate Ringer's Irrigation Solution is the first of such approval for the PRC entities, which is mainly used for general rinsing where sterile electrolyte solutions are permitted. Bumetanide Injection is mainly used for treatment of edema associated with heart failure and renal or hepatic dysfunction, and is also used for prevention of acute renal failure and for treatment of hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH) and acute drug or toxin poisoning. As stated in the Company’s announcement dated 16 March 2026, the Group’s Bumetanide bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 27 March 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.